全文获取类型
收费全文 | 18021篇 |
免费 | 1133篇 |
国内免费 | 591篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 447篇 |
妇产科学 | 215篇 |
基础医学 | 5416篇 |
口腔科学 | 164篇 |
临床医学 | 1547篇 |
内科学 | 3577篇 |
皮肤病学 | 398篇 |
神经病学 | 1202篇 |
特种医学 | 298篇 |
外国民族医学 | 3篇 |
外科学 | 1264篇 |
综合类 | 1851篇 |
现状与发展 | 2篇 |
预防医学 | 759篇 |
眼科学 | 182篇 |
药学 | 1179篇 |
中国医学 | 72篇 |
肿瘤学 | 1117篇 |
出版年
2024年 | 20篇 |
2023年 | 217篇 |
2022年 | 369篇 |
2021年 | 507篇 |
2020年 | 409篇 |
2019年 | 383篇 |
2018年 | 452篇 |
2017年 | 463篇 |
2016年 | 425篇 |
2015年 | 408篇 |
2014年 | 676篇 |
2013年 | 1275篇 |
2012年 | 546篇 |
2011年 | 646篇 |
2010年 | 524篇 |
2009年 | 555篇 |
2008年 | 612篇 |
2007年 | 619篇 |
2006年 | 541篇 |
2005年 | 581篇 |
2004年 | 574篇 |
2003年 | 531篇 |
2002年 | 481篇 |
2001年 | 437篇 |
2000年 | 452篇 |
1999年 | 415篇 |
1998年 | 389篇 |
1997年 | 427篇 |
1996年 | 493篇 |
1995年 | 459篇 |
1994年 | 528篇 |
1993年 | 413篇 |
1992年 | 459篇 |
1991年 | 476篇 |
1990年 | 371篇 |
1989年 | 314篇 |
1988年 | 330篇 |
1987年 | 261篇 |
1986年 | 242篇 |
1985年 | 430篇 |
1984年 | 324篇 |
1983年 | 193篇 |
1982年 | 188篇 |
1981年 | 73篇 |
1980年 | 77篇 |
1979年 | 36篇 |
1978年 | 33篇 |
1977年 | 36篇 |
1976年 | 20篇 |
1970年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Nefrología : publicación oficial de la Sociedad Espa?ola Nefrologia》2022,42(5):578-584
IntroductionThere is no consensus on the most appropriate treatment for chronic active antibody-mediated rejection (cAMR). Recent studies suggest that treatment with tocilizumab (TCZ) may stabilize graft function, decrease the intensity of donor-specific HLA antibodies (DSAs) and reduce inflammation of microcirculation.Patients and methodsObservational study with renal allograft recipients diagnosed with cAMR (n = 5) who had not submitted a response to traditional treatment based on the combination of plasma replacements, immunoglobulins, and rituximab. Patients were told to be treated with TCZ as compassionate use in six doses per month (8 mg/kg/month). Renal function, proteinuria, and the intensity of DSAs were monitored during follow-up.ResultsFive patients, average age 60 ± 13 years, three male and two retrasplants (cPRA average 55%) with preformed DSAs. Treatment with TCZ was initiated within 47 ± 52 days of biopsy. In two cases treatment was discontinued after the first dose, by severe bicitopenia with cytomegalovirus viremia and by graft failure, respectively. In the three patients who completed treatment, no stability of renal function (serum creatinine from 1.73 ± 0.70 to 2.04 ± 0.52 mg/dL, e-FGR 4 6 ± 15 to 36 ± 16 mL/min), showed increased proteinuria (3.2 ± 4.0 to 6.9 ± 11.0 g/g) and the intensity of DSAs maintain stable. No changes were observed in the degree of inflammation of microcirculation (g + pt 4.2 ± 0.8 vs. 4.3 ± 1.0) or in the degree of transplant glomerulopathy (cg 1.2 ± 0.4 vs. 1.8 ± 1.0).ConclusionsTCZ therapy does not appear to be effective in modifying the natural history of chronic active antibody-mediated rejection, does not improve the degree of inflammation of microcirculation and does not reduces the intensity of DSAs. 相似文献
2.
《Immunity》2022,55(9):1725-1731.e4
- Download : Download high-res image (182KB)
- Download : Download full-size image
3.
《Clinical gastroenterology and hepatology》2022,20(5):1112-1121.e4
- Download : Download high-res image (419KB)
- Download : Download full-size image
4.
Yesim Aydinok 《ISBT科学丛刊》2020,15(1):102-109
Lifetime red cell concentrate (RCC) transfusions still account for significant iron overload‐related morbidity and mortality despite chelation therapy in thalassaemia. The cumulative risk of transfusion‐transmitted infections is substantial for thalassaemia patients. Pathogen reduction technologies for RCC may imply a proactive approach against new/re‐emerging pathogens and may be an ultimate safeguard for transfusion safety in the developing countries. Red cell alloimmunization may become a significant clinical challenge in thalassaemia. The availability of high‐throughput molecular blood group antigen typing in the donors may allow perfect match transfusion, beyond ABO‐D and CEK antigen‐matched transfusions. Allogeneic stem cell transplantation (A‐SCT) is the only available curative therapy in thalassaemia, but carries a substantial risk of serious adverse events and mortality. Gene addition therapy for correction of the α‐globin chain imbalance overcomes the problems of donor availability and immunological complications of A‐SCT. Gene editing by either gene disruption or correction emerged as a potential alternative to gene addition therapy in beta‐thalassaemia. A new era of novel therapeutics targeting α/β imbalance, ineffective erythropoiesis or iron dysregulation is unfolding in thalassaemia management, and a number of those now have agents in preclinical and clinical development. Hydroxyurea (HU) may improve globin chain imbalance and be beneficial for reducing or omitting transfusion requirement. Ruxolitinib has allowed steady decrease in spleen volume that may serve for avoiding splenectomy in beta‐thalassaemia. Luspatercept may restore normal erythroid differentiation and improve anaemia. Hepcidin mimetics or TMPRSS6 inhibitors may modulate ineffective erythropoiesis by iron restriction and improve anaemia and organ iron loading. 相似文献
5.
《Vaccine》2020,38(2):115-118
Different strategies have been proposed to overcome maternally derived antibody (MDA) interference with canine parvovirus type 2 (CPV-2) immunisation, including intranasal vaccination, which presents some practical limitations. In the present study, the results of the oral administration of a commercial CPV-2b modified live virus (MLV) vaccine in pups with MDA are reported. The CPV-2b vaccine was orally administered to 14 6-week-old pups with a bait. Blood samples and rectal swabs were collected at different days post-vaccination (dpv) to determine CPV-2 antibody titres and DNA loads. Thirteen pups were positive to serological and virological tests after the first vaccination and one pup became positive after the second vaccine administration. The findings of this study suggest that systemic immunity against CPV-2 may be achieved by the use of an MLV CPV-2b vaccine administered orally even in the presence of MDA titres that usually interfere with vaccination. 相似文献
6.
7.
F. Fruzzetti G. Palla A. Sbrana T. Simoncini M. R. Sessa 《Gynecological endocrinology》2020,36(10):938-940
AbstractObjective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.Methods: A 52-year-old woman with a 2?months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173?ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings. 相似文献
8.
The effect of maternal antibodies on the cellular immune response after infant vaccination: A review
《Vaccine》2020,38(1):20-28
During the last few decades, maternal immunization as a strategy to protect young infants from infectious diseases has been increasingly recommended, yet some issues have emerged. Studies have shown that for several vaccines, such as live attenuated, toxoid and conjugated vaccines, high maternal antibody titers inhibit the infant’s humoral immune response after infant vaccination. However, it is not clear whether this decreased antibody titer has any clinical impact on the infant’s protection, as the cellular immune responses are often equally important in providing disease protection and may therefore compensate for diminished antibody levels. Reports describing the effect of maternal antibodies on the cellular immune response after infant vaccination are scarce, probably because such studies are expensive, labor intensive and utilize poorly standardized laboratory techniques. Therefore, this review aims to shed light on what is currently known about the cellular immune responses after infant vaccination in the presence of high (maternal) antibody titers both in animal and human studies. Overall, the findings suggest that maternally derived antibodies do not interfere with the cellular immune responses after infant vaccination. However, more research in humans is clearly needed, as most data originate from animal studies. 相似文献
9.
10.